Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - powder and solvent for suspension for injection - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - varicella-zoster virus (live, attenuated) - herpes zoster; immunization - viral vaccines - zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia. zostavax is indicated for immunisation of individuals 50 years of age or older.,

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - zoster vaccine live oka/merck -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - varicella-zoster virus live attenuated (oka/merck strain) - powder and solvent for suspension for injection

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaccines - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz.the use of shingrix should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: dibasic sodium phosphate; sodium chloride; urea; potassium chloride; sucrose; monobasic potassium phosphate; monosodium glutamate monohydrate; hydrolysed gelatin - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; sodium chloride; sucrose; hydrolysed gelatin; dibasic sodium phosphate; monobasic potassium phosphate; potassium chloride; urea - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - live varicella vaccine, quantity: 19400 pfu - injection, powder for - excipient ingredients: monosodium glutamate monohydrate; monobasic potassium phosphate; urea; sodium chloride; dibasic sodium phosphate; hydrolysed gelatin; potassium chloride; sucrose - zostavax is indicated for the prevention of herpes zoster (shingles) in individuals 50 years of age and older. zostavax is indicated for the prevention of postherpetic neuralgia (phn) and for reduction of acute and chronic zoster-associated pain in individuals 60 years of age and older.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 19400 [pfu] in 0.65 ml - zostavax® is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. limitations of use of zostavax: - zostavax is not indicated for the treatment of zoster or postherpetic neuralgia (phn). - zostavax is not indicated for prevention of primary varicella infection (chickenpox). do not administer zostavax to individuals with a history of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other component of the vaccine. neomycin allergy manifested as contact dermatitis is not a contraindication to receiving this vaccine. {1} do not administer zostavax to individuals who are immunodeficient or immunosuppressed due to disease or therapy, as serious or fatal disseminated vaccine strain varicella-zoster virus disease may occur. causes of immunodeficiency or immunosuppression may include, but are not limited to, primary or acquired immunodeficiency states, aids or other clinical manifestations of infection with human immunodeficiency

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.